Introduction
Cystic fibrosis (CF)' is the most common severe autosomal recessive disorder in Caucasians. The pathophysiology of the disease is associated with the abnormal regulation of epithelial chloride channels (1) , which determines accumulation of vis- 1 . Abbreviations used in this paper: CF, cystic fibrosis; CFTR, cystic fibrosis transmembrane conductance regulator; RT, reverse transcription.
cous secretions in the lungs and pancreas and abnormal electrolyte composition in the sweat (2) . CF is caused by mutations in the so-termed cystic fibrosis transmembrane conductance regulator (CFTR) gene, which encompasses 27 exons encoding a 1,480-amino acid protein (3) (4) (5) . Structurally, CFTR is similar to the multidrug resistance P-glycoprotein, and is considered a member ofthe ATP-binding cassette superfamily of membrane transporters (4, 6) . CFTR presents two ATP-binding sites, two transmembrane-spanning domains, and a regulatory domain, containing phosphorylation sites, which links the two halves of the protein (4) . Several evidence point out that CFTR is a protein kinase-regulated Cl-channel (7) (8) (9) (10) (11) (12) (13) .
So far 250 mutations have been identified in the CF gene (CF Genetic Analysis Consortium, unpublished data), and 27 ofthese ( 1 3%) produce stop-codons (nonsense mutations). Patients bearing nonsense mutations, such as S1255X, G542X, G553X, and W13 16X, present severe pancreatic insufficiency but mild to moderate pulmonary illness (14) (15) (16) (17) , whereas other patients carrying the WI 282X present differences in the severity of lung involvement (18, 19) . Pancreatic insufficiency and mild to moderate pulmonary disease have also been shown in patients homozygous for a very common nonsense mutation in northeastern Italy (10.2% of the CF chromosomes), which is R 1162X (20, 21) . This mutation is located in exon 19 between the second transmembrane domain and the second nucleotide binding fold, and it is characterized by the substitution of the amino acid arginine in position 1162 ofCFTR with a UGA termination codon. So far there is no basis for claiming a relationship between the type of nonsense mutation and CF phenotype, which is a crucial question that has important implications on both drug and gene therapy.
There is evidence that suggests that the most common CF mutation, dF508, results in a defective processing and localization of the CFTR protein (22) (23) (24) (25) (26) (27) . It was shown that the basis of CFTR dF508 failure was due both to a decreased amount of the protein on the apical membrane and to the reduced time of opening of the mutated CFTR channel (28) . However, not all mutations ofCFTR affect protein processing. For instance, the missense mutation G55 1 D, which is also in the nucleotide binding domain like dF508, produces a normally processed CFTR (22) with a severely reduced function (29) . Therefore CFTR mutations can either cause a defective processing of CFTR or directly decrease CFTR function.
A third different mechanism of CFTR alteration has been suggested by studies on some nonsense mutations, namely G553X (exon 11) and W1316X (exon 21), in which severe reduction of CFTR mRNA and undetectable protein have been reported in respiratory cells (30, 31) . Also, for nonsense mutations of CFTR, the mechanism is probably not univocal, owing to the controversial data presented on the WI 282X mutation (32, 33) . It is already known that in vivo nonsense mu-tations in genes of other human diseases lead either to decreased mRNA accumulation (34) (35) (36) or to normal mRNA levels with production of truncated protein (37-39). In both cases the molecular mechanism is not clearly understood. In order to better understand the pathway by which CFTR nonsense mutations lead to the CF disorder, we investigated the effect of the nonsense mutation RI 162X on the expression of the CF gene. We analyzed the steady-state levels of CFTR mRNA in nasal polyps of a patient homozygous for R 1 62X, and we found a levels oftranscript comparable to that detected in non-CF tissue.
Methods
Experimental subjects. Nasal polyps, excised to relieve airway obstruction, were obtained from a female CF patient homozygote for R I 162X, a CF male homozygote for the phenylalanine deletion at codon 508 (dF508), and non-CF subjects. Tissue specimens were collected in the operating room immediately after the excision and placed in chilled Leibovitz- 1 (42) . 90 ,g/iml ethidium bromide was added to the samples before electrophoresis in order to assess the quality and the amounts of RNA in each lane by visual examination of ribosomal RNA fractions.
As a molecular weight marker 3 Mg of a 0.24-9.5-kb RNA ladder (Gibco BRL, Gaithersburg, MD) was loaded into the gels. The RNA was transferred to Hybond-C extra supported nitrocellulose membranes (Amersham International, Amersham, UK) by capillary blotting (42) for 15-16 h and immobilized on the membrane by incubation at 80°C for 2 h. The filters were prehybridized for 8 h at 42°C in a solution containing 50% formamide (vol/vol), 5X Denhardt's, 0.5% SDS, 5X SSPE (0.9 M NaCl, 50 mM sodium phosphate, pH 7.4,5 mM EDTA), and 250 Mg/ml denatured salmon sperm DNA (Sigma Chemical Co.). The prehybridization mixture was replaced with fresh solution containing 2 X 106 cpm/ml of 32P-labeled Cl-l /5 CFTR cDNA probe (4) (American Type Culture Collection 61160, Rockville, MD) with a specific activity of 1.9 X 109 cpm/Mg. This probe, spanning exons 9-24 of CFTR cDNA, was radiolabeled with [a-32P dCTP (3,000 Ci/ mmol; Amersham International) by random priming using the Multiprime DNA labeling system kit according to the manufacturer's conditions (Amersham International). Hybridization was performed overnight at 42°C and then the blots were washed twice in 2X SSC (lx = 0.15 M NaCl, 15 mM sodium citrate, pH 7.4) solution containing 0.1% of SDS at room temperature for 10 min, followed by two washings in 0.5% SSC, 0.1% SDS at 65°C for 30 min, with continuous shaking. The colon carcinoma cell line T84 was used as a positive control for CFTR mRNA expression. Human fl-actin probe cDNA (43) that hybridized to a 2.0-kb fl-actin mRNA was used as a control probe and to estimate the RNA blotted on the filter. Membranes were exposed to Hyperfilm-MP films (Amersham International) at -80°C with intensifying screens. Laser densitometry, using a model 2202 Ultroscan (LKB-Pharmacia) was used to quantitate the relative signal intensity of the bands obtained and normalized on the basis of ,B-actin mRNA signal to correct for RNA loading.
Results
The expression of CFTR mRNA was initially studied by reverse transcription and PCR amplification. Two sets ofprimers amplifying fragments ofCFTR cDNA spanning exons 5-7 and exons 20-24 were utilized in nasal polyps obtained from one patient homozygous for dF508, one patient homozygous for Rl 162X, and a non-CF subject. To confirm the specificity of the amplification of CFTR, RNA extracted from NIH 3T3 fibroblasts, in which CFTR is not expressed, was included. Fig.  1 A shows the presence of amplified fragments of the expected size from exons 5-7. The signal of the Rl 162X and dF508 samples is present and comparable to that ofthe non-CF polyp while no signal was detectable from the NIH 3T3 sample. The same results were observed utilizing the 20/24 primers, as shown in Fig. 1 B. To increase confidence that our primers were amplifying the expected fragments, restriction enzymes were used to cut the amplified product derived from the Rl 1 62X samples. Bands of the appropriate size were detected after digestion with Dde I (297, 180, 135 bp) and Hinf I (395, 104, 98 bp), giving further evidence to the specificity of the signal.
Since the nasal polyp is a dishomogeneous tissue, the expression of the human cytokeratin 15 (HCK1 5) RNA was checked to assess the epithelial origin of the RNA samples. We have chosen HCK1 5 as an epithelial marker, because the epithelial components of nasal polyps are very similar to those present in trachea (44) where HCK1 5 is expressed in substantial quantities (45 ) . HCK1 5 is clearly expressed in all the polyp samples, as described in Fig. 2 A. In the same experiment no signal was detectable from white blood cell RNA that was used as an additional negative control for the primers. Therefore we can assume that our total RNA is at least in part deriving from respiratory epithelium. Since inflammatory cells deriving from circulating white blood cells could infiltrate the nasal polyp tissue and CFTR mRNA was detected also in lymphocytes by PCR amplification (46), we wanted to exclude that the primers utilized for the amplification of CFTR cDNA were detecting a M Z signal coming from white blood cells. The same primers and protocols were adopted to amplify the cDNA obtained by reverse transcription of 3 gg of RNA extracted from circulating leukocytes. Fig. 2 , B and C, demonstrates that no signal from CFTR is apparent from leukocytes. To check the quality ofthe RNA, primers to human ,B-actin were used and fragments of the expected size were obtained. Therefore we can assume with good confidence that the signal corresponding to CFTR mRNA in the polyp was not derived from leukocytes infiltrating the tissue. The protocol adopted in the previous PCR experiments does not of CFTR mRNA expressed in the nasal polyps of the three different genotypes. For this reason a Northern analysis was performed on the RNA extracted from polyp tissues. Fig. 3 A confirms the presence of CFTR mRNA in all three samples. The data are validated by the detection of the expected 6.5-kb CFTR mRNA size that was clearly expressed in the T84 colon carcinoma cell line. The blots were simultaneously hybridized with a human fl-actin probe to check for the RNA integrity and to correct for the amount of the RNA loaded on the gels.
Autoradiographs were scanned with a laser densitometer and the optical density deriving from CFTR was normalized with that of f3-actin among the different samples. Fig. 3 
Discussion
Our data on the nonsense mutation R 1162X clearly show that the CFTR mRNA is expressed to the same extent both in the CF and non-CF respiratory nasal epithelia, as demonstrated by RT-PCR and Northern analysis. In contrast, it has been already shown that the nonsense mutations R553X and W1316X determine severe reduction of CFTR mRNA (30) .
Nonsense mutations have sometimes been associated with lack of mRNA and protein, as in human f3-globin (34) , human a I-antitrypsin (35) , and insulin receptor (36) genes, while in other cases such as that of the LDL receptor or the apolipoprotein C-II genes a stable truncated protein is synthesized (37, 39) . It has been suggested that mRNAs presenting translation termination mutations might be unstable since they may not be protected by ribosomes from the endogenous RNAase digestion (34) . On the contrary, mRNAs with premature termination codons located toward the 3' end ofthe transcript sometimes seem to escape the higher degradation rate, as occurs with the dihydrofolate reductase gene (47) . Therefore, the effect produced by CFTR mutation RI 162X, which is located toward the 3' end of the gene (amino acid 1162 of 1480), could be consistent with this latter condition. Since nonsense mutation W 1316X, which is even more toward the 3' end, is characterized by a lack of mRNA, one might speculate that conformational modifications of the mRNA specific to each mutation rather than to the position of the mutation itself in the gene are responsible for the protection from RNAse digestion of the transcript. These data may contribute to the further understanding of the molecular mechanisms by which mutations of CFTR gene eventually lead to defective chloride transport in CF epithelial cells. It is now known that CFTR protein is abnormally processed in the presence of deletion or missense mutations as it occurs with dF508, dI507, and S5491 (22) . On the contrary, a mature protein is present in the mutation G551D (22) , in which a defective function is the molecular basis of the defect (29) . Nonsense mutations of CFTR might therefore cause the cellular defect either because of absence of the protein, as in R553X and W 1316X (31) (48) , it is noteworthy to mention that patients homozygous for the R 1162X mutation present defective pancreatic function but mild to moderate lung disease (20) . In parallel with data demonstrated in mutations characterized by a mild pulmonary phenotype such as G55 1S (29), it is possible that RI 162X might express a partially functional protein, at least in the respiratory epithelia. We checked protein expression in the same nasal tissues by immunoprecipitation and Western analysis, but the level of protein in non-CF samples is below detectability (data not shown).
In conclusion, the mutation R 1162X results in normally expressed CFTR mRNA, indicating that nonsense mutations of the CFTR gene have heterogeneous mechanisms of mRNA processing (e.g., degradation). The presence of the transcript in respiratory cells of patients with mild to moderate lung disease could suggest that a partially functional protein could be expressed at least in the airway tract.
